<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789358</url>
  </required_header>
  <id_info>
    <org_study_id>FIHCValencia</org_study_id>
    <nct_id>NCT02789358</nct_id>
  </id_info>
  <brief_title>A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>plusONE</acronym>
  <official_title>A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation. Results of the the plusONE Randomized Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to validate a new dosage of cryotherapy based on time to effect in pulmonary
      vein ablation procedures in patients with paroxysmal atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation-free survival, without antiarrhythmic drug therapy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean number of cryotherapy applications per patient to complete isolation</measure>
    <time_frame>Intraprocedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cryotherapy time</measure>
    <time_frame>Intraprocedure</time_frame>
    <description>Total cryotherapy time of applications needed per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required to complete isolation of all the pulmonary veins (LA time)</measure>
    <time_frame>Intraprocedure</time_frame>
    <description>Time from the end of transeptal approach until the withdrawal of the cryoballoon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time</measure>
    <time_frame>Intraprocedure</time_frame>
    <description>Time from the local anesthesia is administrated until the whole procedure is finished</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute reconnection of pulmonary veins</measure>
    <time_frame>Intraprocedure</time_frame>
    <description>Number of veins reconnected after a 30 minutes waiting period since the end of procedure and with adenosine test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Intraprocedure</time_frame>
    <description>Number of participants with procedural-related adverse events as assessed by by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of atrial fibrillation episodes monitored by Nuubo system</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time in atrial fibrillation monitored by Nuubo system</measure>
    <time_frame>12 months</time_frame>
    <description>Total time in atrial fibrillation monitored by Nuubo system in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation burden detected by Nuubo system</measure>
    <time_frame>12 Months</time_frame>
    <description>total time in atrial fibrillation related to the hole time of monitoring (percentage)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional protocol for cryoablation:
At least 2 applications of 180s each</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental protocol for cryoablation:
Time to effect + 1 minute and a bonus application of 120s</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional cryotherapy dosage</intervention_name>
    <description>Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental cryotherapy dosage</intervention_name>
    <description>cryotherapy dosage: applications &quot;time to block of the vein&quot; plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arctic Front Advance ST Cryoenergy Balloon Catheter</intervention_name>
    <description>Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine triphosphate</intervention_name>
    <description>12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nECG platform Nuubo®</intervention_name>
    <description>30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with at least 2 documented episodes of paroxysmal Atrial Fibrillation (AF)
             which are not responders to at least one antiarrythmic drug

        Exclusion Criteria:

          -  Previous left atrial ablation procedure or surgery

          -  left atrium diameter &gt; 50mm

          -  presence of intracardiac thrombus

          -  Left ventricular ejection fraction &lt; 40%

          -  Heart failure class III-IV

          -  Severe valvulopathies

          -  Acute coronary syndrome or cardiac surgery within the previous 3 months of enrollment

          -  Transient ischemic attack/stroke within the previous 6 months of enrollment

          -  life expectancy less than 1 year

          -  Any contraindication to the procedure according to the current clinical practice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ángel Ferrero De Loma-Osorio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ángel Ferrero De Loma-Osorio, MD, PhD</last_name>
    <phone>0034 96 1973806</phone>
    <email>angelferrero@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo Ruiz Granell, Md, PhD</last_name>
    <phone>0034 96 1973806</phone>
    <email>ricardo.ruizgranell@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Ferrero De Loma-Osorio, PhD MD</last_name>
      <phone>+341973977</phone>
      <email>angelferrero@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marta Peiró, PhD</last_name>
      <phone>+341973536</phone>
      <email>mpeiro@incliva.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>Angel Ferrero</investigator_full_name>
    <investigator_title>MD-PhD</investigator_title>
  </responsible_party>
  <keyword>cryotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

